Glenmark Pharmaceuticals, a wholly-owned Swiss subsidiary of Glenmark Pharmaceuticals, announced that GBR 900, a novel monoclonal antibody is entering human trials. GBR 900 targets TrkA, a receptor for nerve growth factor (NGF) involved in chronic pain signalling.
In 2010, Glenmark gained an exclusive worldwide license from Lay Line Genomics (Italy) for anti-TrkA antibodies and their entire intellectual property portfolio in the TrkA field. GBR 900 is the optimised anti-TrkA antibody emerging from this exclusive worldwide license.
EP News Bureau- Mumbai